A Phase 3 interventional study of Orforglipron and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 80 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).
Participation in the study will last about 18 months.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's planned enrollment of 800 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening:
Exclusion Criteria:
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive orforglipron orally
Drug: Orforglipron
Participants will receive placebo orally
Drug: Placebo
Administered orally
Also known as: LY3502970
Administered orally
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 72
Percentage of Participants Achieving Weight Reduction of ≥5%
Time frame: Baseline up to 72 weeks
Change from Baseline in Waist Circumference
Time frame: Baseline up to 72 weeks
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 72
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline up to 72 weeks
Percent Change from Baseline in Triglycerides
Time frame: Baseline up to 72 weeks
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline up to 72 weeks
Change from Baseline in Fasting Glucose
Time frame: Baseline up to 72 weeks
Change from Baseline in EQ-5D-5L
Time frame: Baseline, Week 72
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC-ss) of Orforglipron
Time frame: Predose through Week 48
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company